Calistoga Shows Cancer Drug Mechanism

6/14/10Follow @xconomy

Calistoga Pharmaceuticals, the Seattle-based developer of drugs for cancer and inflammatory diseases, said today its lead candidate for blood cancers appears to be working against tumors by disrupting chemokine signals and the tumor microenvironment. The findings were presented today at the European Hematology Association meeting in Barcelona. We reported last week on how the Calistoga drug, CAL-101, appears to be shrinking tumors in patients with chronic lymphocytic leukemia, slow-growing forms of non-Hodgkin’s lymphoma, and mantle cell lymphoma.

By posting a comment, you agree to our terms and conditions.